RxDoctor Payments Data

Christina Senesac, APRN

Family · Gulf Breeze, FLNPI 1720560253

Payments from drug & device makers

$1,849in general payments, 2019–2025

Across 29 payments — averaging $63.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$405
  • Lilly USA, LLC$246
  • Neurocrine Biosciences, Inc.$234
  • Edwards Lifesciences$123
  • Johnson & Johnson$122
  • Esperion Therapeutics, Inc.$115
  • plus $603 from 9 others

What the payments were for

  • Food & beverage$1,849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,849 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$57,378
Medicare patients
311
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$85,242
MounjaroTirzepatide59$61,124
EliquisApixaban46$44,996
JanuviaSitagliptin Phosphate45$30,096
JardianceEmpagliflozin35$27,760
TrulicityDulaglutide20$26,106
XareltoRivaroxaban15$22,383
LinzessLinaclotide13$8,076
Atorvastatin Calcium302$3,776
Omeprazole185$2,542
Carbamazepine ErCarbamazepine12$2,493
SynthroidLevothyroxine Sodium20$2,289
Albuterol Sulfate HfaAlbuterol Sulfate76$2,212
Pantoprazole Sodium156$1,918
Amlodipine Besylate246$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$246$87,22979 claims
Novo NordiskOzempic$74$85,24280 claims
PfizerEliquis$32$44,99646 claims
Johnson & JohnsonXarelto$122$22,38315 claims
AbbVieLinzess, Synthroid$85$10,36533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Gulf Breeze

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →